FDA Press Announcement | February 23, 2026
The FDA announced a new framework and draft guidance aimed at helping sponsors generate evidence of safety and effectiveness when randomized trials are not feasible because patient populations are extremely small. This is one of the clearest recent statements of FDA intent to create more workable pathways for ultra-rare disease therapies.
